Allergan, Inc. (NYSE:AGN) Received its Third Buy in a Row

After Leerink Swann and UBS assigned a Buy rating to Allergan, Inc. in the last month, the company received another Buy, this time from Canaccord Genuity. Analyst Corey Davis maintained a Buy rating on Allergan, Inc. (NYSE: AGN) yesterday and set a price target of $396. The company’s shares closed yesterday at $326.98, close to its 52-week high of $334.38.

Allergan has an analyst consensus of Hold.

Based on Allergan`s latest earnings report from March 31, the company posted quarterly revenue of $4.23B and quarterly net profit of -$512M. In comparison, last year the company earned revenue of $2.67B and had a net profit of $48.7M.

Financial bloggers on sites such as, SeekingAlpha and others, seem to have a Positive view on AGN. When evaluating the opinions of financial bloggers over the last 3 months, 80% of bloggers have indicated a Bullish sentiment, while 20% have indicated a Bearish sentiment.

Unlike Canaccord Genuity`s latest rating, based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. Most recently, in February 2014, Louis Lavigne, a director at AGN sold 5,400 shares for a total of $679,212.

According to, Davis is a 5-star analyst with an average return of 18.7%and a 56.5% success rate. Davis covers the Healthcare sector, focusing on stocks such as Aquinox Pharmaceuticals, Infotek Pharmaceuticals, and Pacira Pharmaceuticals.